Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is mor…

[Read more →]

Acute pyelonephritis in adults: a case series of 223 patients.
Nephrol Dial Trans…

[Read more →]

Medical management of hepatorenal syndrome.
Nephrol Dial Transplant. 2012 Jan;27(…

[Read more →]

The fallacy of the BUN:creatinine ratio in critically ill patients.
Nephrol Dial …

[Read more →]

Severe acute kidney injury not treated with renal replacement therapy: characteristics and outcome.
Nephrol Dial Transplant. 2011 Sep 8;
Authors: Schneider AG, Uchino S, Bellomo R
Abstract
BACKGROUND: Only a pr…

[Read more →]

Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.
Nephrol Dial Transplant. 2011 Aug 26;
Authors: Kitchlu A, Clemens K, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Manno M, Olive…

[Read more →]

Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
…

[Read more →]

Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients.
Nephrol Dial Transplant. 2011 Aug 2;
Authors: Lindner G, Schwarz C, Funk GC
BACKGROUND: Hypernatraemia is common in critically ill…

[Read more →]

Early nephrology consultation can have impact on outcome of acute kidney injury patients.
Nephrol Dial Transplant. 2011 Jul 15;
Authors: Ponce D, Zorzenon CD, Santos NY, Balbi AL
BACKGROUND: Patients who develop acute …

[Read more →]

Low pleural fluid-to-serum glucose gradient indicates pleuroperitoneal communication in peritoneal dialysis patients: presentation of two cases and a review of the literature.
Nephrol Dial Transplant. 2011 Jul 19;
Authors: Mom…

[Read more →]

A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury.
Nephrol Dial Transplant. 2011 Jun 9;
Authors: Bagshaw SM, Haase M, Haase-Fielitz A, Bennett M, Devarajan P, Bellomo R
BACKGROUN…

[Read more →]

Acute kidney injury in patients admitted to a liver intensive therapy unit with paracetamol-induced hepatotoxicity.
Nephrol Dial Transplant. 2011 Jun 6;
Authors: O’ Riordan A, Brummell Z, Sizer E, Auzinger G, Heaton N, O’Grady…

[Read more →]

Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients.
Nephrol Dial Transplant. 2011 May 17;
Authors: Ei Amari EB, Hadaya K, Bühler L, Berney T, Rohner P, Martin PY, Mentha G, van Delden C
…

[Read more →]

Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis.
Nephrol Dial Transplant. 2011 May 4;
Authors: Lopes JA, Melo MJ, Viegas A, Raimundo M, Câmara I, Antunes F, Gomes da Costa A
BACKGROUND: Ac…

[Read more →]

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.

Nephrol Dial Transplant. 2011 Mar 3;

Authors: Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Maria Manfreda V, Gentile G, Strippoli GF

BACKGROUND: A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors. METHODS: MEDLINE, EMBASE and Renal Health Library were searched for trials comparing ACEI, ARB or their combination with placebo or with one another in people with albuminuria and one or more cardiovascular risk factor. RESULTS: Eighty-five trials (21 708 patients) were included. There was no significant reduction in the risk of all-cause mortality or fatal cardiac-cerebrovascular outcomes with ACEI versus placebo, ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI versus placebo but not with ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI + ARB versus monotherapy. Development of end-stage kidney disease and progression of microalbuminuria to macroalbuminuria were reduced significantly with ACEI versus placebo and ARB versus placebo but not with combined therapy with ACEI + ARB versus monotherapy. CONCLUSIONS: ACEI and ARB exert independent renal and nonfatal cardiovascular benefits while their effects on mortality and fatal cardiovascular disease are uncertain. There is a lack of evidence to support the use of combination therapy. A comparative clinical trial with ACE, ARB and its combination in people with albuminuria and a cardiovascular risk factor is warranted.

PMID: 21372254 [PubMed - as supplied by publisher]

[Read more →]